GSK: discontinues development of ulcerative colitis drug
(CercleFinance.com) - GSK has decided to discontinue a Phase II clinical trial evaluating Immutep's monoclonal antibody in patients with active ulcerative colitis, the biotechnology firm said on Friday.
Immutep, an Australian research company that focuses on the treatment of cancer and auto-immune diseases, said that GSK has halted the trial based on the assessment of clinical data as part of a planned interim analysis conducted with the trial's data review committee.
GSK is performing further analyses of the efficacy and safety data to determine the next steps for the development of the antibody, named GSK2831781, Immutep said.
The biotech company said that it continues to collaborate with the British healthcare group, with GSK2831781 still under an exclusive license.
Copyright (c) 2021 CercleFinance.com. All rights reserved.